Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. (CTTQ) today announced entering into astrategic alliance to discover, develop and commercialize next-generation biologicsfor multiple therapeutic targets in oncology and immunology.
The collaboration will combine Harbour BioMed’s discovery capabilities, including its transgenic mouse technologies forgenerating fully human antibodies,with CTTQ’s preclinical development resources and expertise. The companies will be responsible for clinical development and commercialization of the rapeutic candidates emerging from the collaboration in their respective regions. Harbour BioMed will be responsible for the United States, Japan, and the rest of the world outside,while CTTQ will have responsibility for Greater China and Europe. The companies will pay royalties to each other based on sales in their respective territories. Additional financial terms were not disclosed.
“The agreement with CTTQ, is part of our strategy to build a robust therapeutic pipeline for global markets through co-discovery, development and commercialization partnerships that capitalize on our patented platforms for generating fully human antibodies,” said Dr. Jingsong Wang, Founder,Chairman and CEO of Harbour BioMed. “CTTQ, a well-known pharmaceutical company that is making strategic investments in therapeutic innovation in oncology and immunology, is a strong partner in that effort and directly complements our internal discovery programs.” added Dr. Wang. It is expected that both sides will jointly own the IP and development and commercialization rights for the new drugs coming out of this collaboration.
“CTTQ will be committed to bring valuable treatment agents for diseases with unmet need. The collaboration with Harbour BioMed is well aligned with CTTQ’s strategy for innovative biological medicine development, it also marks significant progress to strengthen our capability of R&D of innovative therapeutic antibodies.” said Shanchun Wang, President of CTTQ. CTTQ currently has several monoclonal antibody drugs, includinga PD-L1 inhibitor, which have progressed into Phase 2 and Phase 3 clinical development.